Alnylam Pharmaceuticals Inc (ALNY)vsNuCana PLC (NCNA)
ALNY
Alnylam Pharmaceuticals Inc
$298.76
-4.49%
HEALTHCARE · Cap: $41.79B
NCNA
NuCana PLC
$1.34
+8.06%
HEALTHCARE · Cap: $5.66M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. NCNA trades at a lower P/E of 0.0x. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
NCNA
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.3%
Fair Value
$2354.68
Current Price
$298.76
$2055.92 discount
Intrinsic value data unavailable for NCNA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.1x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : NCNA
The strongest argument for NCNA centers on P/E Ratio, Price/Book, Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 78.8x leaves little room for execution misses.
Bear Case : NCNA
The primary concerns for NCNA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a growth stock while NCNA is a value play — different risk/reward profiles.
NCNA carries more volatility with a beta of 2.24 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 26/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
NuCana PLC
HEALTHCARE · BIOTECHNOLOGY · USA
NuCana plc, a clinical-stage biopharmaceutical company, is dedicated to the development of products for the treatment of cancer. The company is headquartered in Edinburgh, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?